North America Startup Funding Rounds

Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027.

Fab2 develops chipmaking equipment and design software to shorten the path from chip design to fabrication.

BrainChild Bio develops CAR T-cell therapies for tumors in the central nervous system, including pediatric brain cancers and glioblastoma.

The developer of Ignite0, a conversational CAD tool that turns text and images into editable three-dimensional models.

ParlayX provides institutional trading desks with a shared control and execution layer for prediction markets, including segregated capital, trader and bot permissions, non-custodial key management and order routing across venues.

Provides a cloud inference platform and compiler that distribute AI workloads across different processor types.

Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical.

Cloud simulation software helps robotics and autonomy teams develop and test physical AI systems before deployment.

Emberos gives brands a system to track how AI assistants represent them, understand the sources and narratives behind those answers, and take and measure actions intended to improve their visibility and accuracy across AI platforms.

DivergeIT provides managed IT and cybersecurity services to U.S. businesses, combining help-desk support and management of devices, networks and cloud systems with security monitoring and response.